Activin-βCmodulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways
Open Access
- 23 May 2015
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 6 (4) , 365-380
Abstract
Background Cancer-associated cachexia and muscle wasting are considered key determinants of cancer-related death and reduction in the quality of life of cancer patients. A crucial link has been established between activin signaling and skeletal muscle atrophy-hypertrophy. We previously showed that activin-βC, a novel activin-A antagonist, is a tumor modulator that abolishes the cancer-associated cachexia in a mouse genetic model of gonadal tumorigenesis, in which the normal balance of inhibin/activin signalling is disrupted by a targeted mutation in the Inha gene (inhibin α-KO mouse). This study aimed to identify the molecular mechanism by which activin-βC increases survival and abolishes cancer-associated cachexia in α-KO mice. We hypothesized that overexpression of activin-βC modulates the cachexia phenotype by antagonizing the activin signaling pathway and repressing muscle wasting via the ubiquitin-proteasome and the autophagic-lysosomal degradation pathways. Methods Male and female ActC++, α-KO, and α-KO/ActC++ mice and WT littermate controls were studied. Western blot analysis for the specific E3 ubiquitin ligases, atrogin-1 and MuRF1, markers of the autophagic-lysosomal pathway, Beclin-1, p62, and LC3A/B, effectors Smad-2, Smad-3 and myostatin was performed in the gastrocnemius of age-matched mice. Histopathology of the gastrocnemius and survival analysis were also conducted in animals from the same breeding cohort. Serum levels of activin-A, inflammatory cytokines, hormonal profile, and bone density were also assessed. Results Increased levels of atrogin-1, MuRF-1, Beclin-1, p62, LC3A/B-I, Smad-2 and serum levels of activin-A were noted in the α-KO mice. These mice developed gonadal cancers followed by severe weight loss, and reduced survival. Overexpression of activin- βC antagonized the activin signaling cascade, attenuating the ubiquitin-proteasome and the autophagic-lysosomal degradation pathways, and reduced serum levels of activin-A. α-KO/ActC++ mice displayed a less aggressive cachectic phenotype, reduced tumor weight, and prolonged survival. Conclusion Our findings show for the first time a specific effect of activin-βC on muscle wasting and transcription factors involved in muscle protein degradation. The study indicates that activin-βC may be a novel therapy to abrogate cancer-associated weight loss and prolong survival.Keywords
Funding Information
- National Health and Medical Research (1008058)
This publication has 38 references indexed in Scilit:
- Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexiaThe American Journal of Clinical Nutrition, 2013
- Autophagic Degradation Contributes to Muscle Wasting in Cancer CachexiaThe American Journal of Pathology, 2013
- Effects of inflammatory and anti‐inflammatory cytokines on the boneEuropean Journal of Clinical Investigation, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Regulation of Muscle Mass by Follistatin and ActivinsMolecular Endocrinology, 2010
- Autophagy in skeletal muscleFEBS Letters, 2010
- Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexiaBiochemical and Biophysical Research Communications, 2010
- Animal models of anorexia and cachexiaExpert Opinion on Drug Discovery, 2009
- During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylationJournal of Cell Biology, 2009
- Activin C Antagonizes Activin A in Vitro and Overexpression Leads to Pathologies in VivoThe American Journal of Pathology, 2009